[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363361-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363361-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","iron-status-erythropoietin-and-cancer-incidence-in-the-general-population","Iron Status, Erythropoietin, and Cancer Incidence in the General Population","","Background: Iron is essential for cellular function and cancer growth, but epidemiological results on iron imbalance remain inconsistent. Erythropoietin (EPO) may also affect tumour progression. The study evaluated associations among iron status, EPO levels, and cancer incidence in the general population. Method: Baseline iron biomarkers (ferritin, transferrin saturation, sTfR, hepcidin) and EPO were measured in 6109 PREVEND participants and followed for outcomes. Results: Over median 18.5 years, higher EPO linked to increased overall cancer risk, whereas higher hepcidin linked to reduced risk. Patterns persisted after excluding early diagnoses.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/iron-status-erythropoietin-and-cancer-incidence-in-the-general-population/363361/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/iron-status-erythropoietin-and-cancer-incidence-in-the-general-population/363361.png","ImageObject",300,407,{"name":42,"@type":43},"eBook King","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What were the main variables measured in the PREVEND cohort?","Question",{"text":63,"@type":64},"Iron biomarkers including ferritin, transferrin saturation, soluble transferrin receptor (sTfR), hepcidin, and erythropoietin (EPO) were measured at baseline.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did EPO and hepcidin relate to overall cancer risk?",{"text":68,"@type":64},"Higher EPO was associated with increased overall cancer risk, while elevated hepcidin was associated with a lower cancer risk.",{"name":70,"@type":61,"acceptedAnswer":71},"Did the associations change after excluding early cancer diagnoses?",{"text":72,"@type":64},"Yes, the increased risk with higher EPO and the decreased risk with higher hepcidin remained significant after excluding early diagnoses, supporting robustness of the findings.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363361,1790620140,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962088006270,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","European Journal of Clinical Investigation  \nORIGINAL ARTICLE  OPEN ACCESS   \nIron Status, Erythropoietin, and Cancer Incidence in the General Population  \nSiem J. van Alfen1  | Pien Rawee2 | Li Luo2  | Ilja M. Nolte3 | Bert van der Vegt4 | Jenny E. Kootstra-Ros5 | Stephan J. L. Bakker2 | Ron T. Gansevoort2 | Thera P. Links1 | Wouter T. Zandee1 | Michele F. Eisenga2  \n1Division of Endocrinology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands | 2Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands | 3Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands | 4Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands | 5Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands  \nCorrespondence: Michele F. Eisenga ([m.f.eisenga@umcg.nl](m.f.eisenga@umcg.nl))  \nReceived: 22 December 2025 | Revised: 27 March 2026 | Accepted: 28 April 2026  \nKeywords: cancer risk | EPO levels | general population | iron status | site-specific cancer  \nABSTRACT  \nBackground: Iron is essential for cellular function and cancer growth. While iron imbalance has been implicated in cancer development, epidemiological evidence remains inconsistent. Erythropoietin (EPO) may influence tumour progression. We aimed to investigate the associations between iron status, EPO levels, and cancer incidence in the general population.  \nMethod: Data were obtained from 6109 participants (mean age 52 ± 12years; 49% male) in the Prevention of Renal and Vascular End-stage Disease (PREVEND) cohort. Iron biomarkers, including ferritin, transferrin saturation, soluble transferrin receptor (sTfR), hepcidin and EPO levels, were measured at baseline.  \nResults: Over a median 18.5 year follow-up, 1090 participants developed cancer. Multivariable Cox regression revealed that higher EPO (HR 1.26; 95% CI 1.07–1.47; p = 0.005) was associated with increased overall cancer risk, while elevated hepcidin levels were associated with a lower risk (HR 0.88; 95% CI 0.80–0.96; p = 0.006). Higher sTfR (HR 1.35; 95% CI 1.01–1.80; p = 0.043) was suggestive for an increased risk of overall cancer. After excluding early diagnoses, the increased risk associated with higher EPO levels and decreased risk associated with higher hepcidin levels remained significant. Lower transferrin saturation was associated with increased haematological cancer risk, while higher hepcidin was associated with reduced gastrointestinal cancer risk, especially in women and those with BMI \u003C 25 kg/m2 . In non-smokers, higher sTfR and EPO were associated with increased overall and kidney cancer.  \nConclusion: These findings underscore the putative roles of iron metabolism and EPO in cancer, with consistently decreased risks associated with elevated hepcidin levels, particularly among women and individuals with lower BMI.  \n1 | Introduction  \nIron is an essential micronutrient involved in oxygen transport, DNA synthesis and energy production [1]. Iron is pivotal for red blood cell formation and supports key functions in brain and cardiovascular health [2] . Disordered iron homeostasis has been  \nimplicated in numerous diseases, ranging from heart failure to neurological disorders [3, 4] .  \nIron metabolism is also frequently altered in cancer. Elevated intracellular iron increases the labile iron pool, promoting reactive oxygen species formation, which can damage DNA and foster  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s). European Journal of Clinical Investigation published by John Wiley & Sons Ltd on be","cbCaifGcjk4qbvW3","https://ap.wps.com/l/cbCaifGcjk4qbvW3","pdf",1648018,"English","# Abstract\n## Background\n## Method\n## Results\n## Conclusion\n# Introduction\n# Methods\n## Study Design and Population","[{\"question\":\"What were the main variables measured in the PREVEND cohort?\",\"answer\":\"Iron biomarkers including ferritin, transferrin saturation, soluble transferrin receptor (sTfR), hepcidin, and erythropoietin (EPO) were measured at baseline.\"},{\"question\":\"How did EPO and hepcidin relate to overall cancer risk?\",\"answer\":\"Higher EPO was associated with increased overall cancer risk, while elevated hepcidin was associated with a lower cancer risk.\"},{\"question\":\"Did the associations change after excluding early cancer diagnoses?\",\"answer\":\"Yes, the increased risk with higher EPO and the decreased risk with higher hepcidin remained significant after excluding early diagnoses, supporting robustness of the findings.\"}]","Iron Status, Erythropoietin, and Cancer Incidence in the General Population | PDF",1790150938,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e00cbff34a5ee8a0e9d7c6f04477600c.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6cdcc30546734fb277e7c0a8c9c223b9.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1708584b8d51cac75ac1daf3469d2298.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d03e0d719bfe685b18a1e12f48cf38c8.webp",980,1287]